{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:54:15Z","timestamp":1791302055493,"version":"4.1.0"},"reference-count":214,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>HIV has challenged humanity for decades, quietly establishing latent reservoirs that evade even the most potent antiretroviral therapies (ART). While ART transformed HIV from a fatal disease into a manageable condition, the virus\u2019s hidden persistence continues to fuel the global epidemic. This review narrates the story of HIV treatment, tracing the evolution of therapeutic strategies from conventional ART to innovative gene-editing and immunotherapeutic approaches. Central to this journey is the CRISPR-Cas system, a molecular scalpel that has enabled precise excision of integrated proviral DNA, disruption of entry co-receptors like CCR5, and modulation of host restriction factors to bolster innate defenses. Preclinical studies reveal that CRISPR interventions can reduce viral reservoirs, prevent reactivation, and restore antiviral immunity, offering a glimpse of a future beyond lifelong ART. Challenges remain, notably efficient delivery to infected cells and minimizing off-target effects, but advances in vector design and computational prediction tools are steadily overcoming these barriers. By weaving experimental findings with translational perspectives, this review highlights CRISPR\u2019s potential to provide durable, scalable, and cost-effective HIV control, particularly in low-resource settings. Ultimately, this narrative underscores a hopeful vision: that precise gene editing may transform HIV therapy from lifelong suppression into a pathway toward functional cure, changing the story of the virus and the lives it touches.<\/jats:p>","DOI":"10.1007\/s13365-026-01343-5","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:27:24Z","timestamp":1789403244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HIV cure: from early therapies to cutting-edge strategies"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9507-8174","authenticated-orcid":false,"given":"Zahra","family":"Safaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"1343_CR1","doi-asserted-by":"publisher","unstructured":"Allen AG, Chung C-H, Atkins A, Dampier W, Khalili K, Nonnemacher MR, Wigdahl B (2018) Gene editing of HIV-1 co-receptors to prevent and\/or cure virus infection [Review]. Front Microbiol 9\u20132018. https:\/\/doi.org\/10.3389\/fmicb.2018.02940","DOI":"10.3389\/fmicb.2018.02940"},{"issue":"2","key":"1343_CR2","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1016\/s2352-3018(18)30295-9","volume":"6","author":"KN Althoff","year":"2019","unstructured":"Althoff KN, Gebo KA, Moore RD, Boyd CM, Justice AC, Wong C, Lucas GM, Klein MB, Kitahata MM, Crane H, Silverberg MJ, Gill MJ, Mathews WC, Dubrow R, Horberg MA, Rabkin CS, Klein DB, Re L, Sterling V, Gange TR, S. J (2019) Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. Lancet HIV 6(2):e93\u2013e104. https:\/\/doi.org\/10.1016\/s2352-3018(18)30295-9","journal-title":"Lancet HIV"},{"issue":"9","key":"1343_CR3","doi-asserted-by":"publisher","first-page":"e652","DOI":"10.1016\/S2352-3018(20)30117-X","volume":"7","author":"RF Ambinder","year":"2020","unstructured":"Ambinder RF, Capoferri AA, Durand CM (2020) Haemopoietic cell transplantation in patients living with HIV. Lancet HIV 7(9):e652\u2013e660","journal-title":"Lancet HIV"},{"issue":"7785","key":"1343_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, Chen PJ, Wilson C, Newby GA, Raguram A (2019) Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576(7785):149\u2013157","journal-title":"Nature"},{"issue":"7408","key":"1343_CR5","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nature11286","volume":"487","author":"NM Archin","year":"2012","unstructured":"Archin NM, Liberty A, Kashuba AD, Choudhary SK, Kuruc J, Crooks A, Parker D, Anderson E, Kearney M, Strain M (2012) Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487(7408):482\u2013485","journal-title":"Nature"},{"issue":"4","key":"1343_CR6","doi-asserted-by":"publisher","first-page":"a007161","DOI":"10.1101\/cshperspect.a007161","volume":"2","author":"EJ Arts","year":"2012","unstructured":"Arts EJ, Hazuda DJ (2012) HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2(4):a007161. https:\/\/doi.org\/10.1101\/cshperspect.a007161","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1343_CR7","doi-asserted-by":"publisher","first-page":"102728","DOI":"10.1016\/j.jddst.2021.102728","volume":"65","author":"B Ashok","year":"2021","unstructured":"Ashok B, Peppas NA, Wechsler ME (2021) Lipid- and polymer-based nanoparticle systems for the delivery of CRISPR\/Cas9. J Drug Deliv Sci Technol 65:102728. https:\/\/doi.org\/10.1016\/j.jddst.2021.102728","journal-title":"J Drug Deliv Sci Technol"},{"key":"1343_CR8","doi-asserted-by":"publisher","first-page":"155785","DOI":"10.1016\/j.prp.2024.155785","volume":"266","author":"AK Balaraman","year":"2025","unstructured":"Balaraman AK, Babu MA, Moglad E, Mandaliya V, Rekha MM, Gupta S, Prasad GVS, Kumari M, Chauhan AS, Ali H, Goyal K (2025) Exosome-mediated delivery of CRISPR-Cas9: A revolutionary approach to cancer gene editing. Pathol - Res Pract 266:155785. https:\/\/doi.org\/10.1016\/j.prp.2024.155785","journal-title":"Pathol - Res Pract"},{"issue":"1","key":"1343_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00281-004-0165-3","volume":"26","author":"F Baron","year":"2004","unstructured":"Baron F, Storb R (2004) Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. Springer Semin Immunopathol 26(1):71\u201394. https:\/\/doi.org\/10.1007\/s00281-004-0165-3","journal-title":"Springer Semin Immunopathol"},{"issue":"5819","key":"1343_CR10","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1126\/science.1138140","volume":"315","author":"R Barrangou","year":"2007","unstructured":"Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P (2007) CRISPR provides acquired resistance against viruses in prokaryotes. Science 315(5819):1709\u20131712. https:\/\/doi.org\/10.1126\/science.1138140","journal-title":"Science"},{"issue":"1","key":"1343_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41572-023-00452-3","volume":"9","author":"L-G Bekker","year":"2023","unstructured":"Bekker L-G, Beyrer C, Mgodi N, Lewin SR, Delany-Moretlwe S, Taiwo B, Masters MC, Lazarus JV (2023) HIV infection. Nat Reviews Disease Primers 9(1):42. https:\/\/doi.org\/10.1038\/s41572-023-00452-3","journal-title":"Nat Reviews Disease Primers"},{"issue":"6","key":"1343_CR12","doi-asserted-by":"publisher","first-page":"e0158294","DOI":"10.1371\/journal.pone.0158294","volume":"11","author":"JK Bialek","year":"2016","unstructured":"Bialek JK, Dunay GA, Voges M, Sch\u00e4fer C, Spohn M, Stucka R, Hauber J, Lange UC (2016) Targeted HIV-1 latency reversal using CRISPR\/Cas9-derived transcriptional activator systems. PLoS ONE 11(6):e0158294","journal-title":"PLoS ONE"},{"key":"1343_CR13","doi-asserted-by":"publisher","unstructured":"Binda CS, Klaver B, Berkhout B, Das AT (2020) CRISPR-Cas9 Dual-gRNA attack causes mutation, excision and inversion of the HIV-1 proviral DNA. Viruses 12(3). https:\/\/doi.org\/10.3390\/v12030330","DOI":"10.3390\/v12030330"},{"issue":"1","key":"1343_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1146\/annurev-immunol-051116-052433","volume":"35","author":"S Bournazos","year":"2017","unstructured":"Bournazos S, Wang TT, Dahan R, Maamary J, Ravetch JV (2017) Signaling by antibodies: recent progress. Annu Rev Immunol 35(1):285\u2013311","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"1343_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jmb.2011.04.021","volume":"410","author":"JA Briggs","year":"2011","unstructured":"Briggs JA, Kr\u00e4usslich H-G (2011) The molecular architecture of HIV. J Mol Biol 410(4):491\u2013500","journal-title":"J Mol Biol"},{"issue":"5","key":"1343_CR16","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2018.04.016","volume":"70","author":"EK Brinkman","year":"2018","unstructured":"Brinkman EK, Chen T, de Haas M, Holland HA, Akhtar W, van Steensel B (2018) Kinetics and Fidelity of the Repair of Cas9-Induced Double-Strand DNA Breaks. Mol Cell 70(5):801\u2013813e806. https:\/\/doi.org\/10.1016\/j.molcel.2018.04.016","journal-title":"Mol Cell"},{"issue":"5891","key":"1343_CR17","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1126\/science.1159689","volume":"321","author":"SJ Brouns","year":"2008","unstructured":"Brouns SJ, Jore MM, Lundgren M, Westra ER, Slijkhuis RJ, Snijders AP, Dickman MJ, Makarova KS, Koonin EV, van der Oost J (2008) Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 321(5891):960\u2013964. https:\/\/doi.org\/10.1126\/science.1159689","journal-title":"Science"},{"key":"1343_CR19","doi-asserted-by":"publisher","unstructured":"Cao W, Mehraj V, Kaufmann DE, Li T, Routy JP (2016) Elevation and persistence of CD8 T-cells in HIV infection: the Achilles heel in the ART era. J Int AIDS Soc 19(1):20697. https:\/\/doi.org\/10.7448\/ias.19.1.2069720697","DOI":"10.7448\/ias.19.1.2069720697"},{"issue":"7","key":"1343_CR18","doi-asserted-by":"publisher","first-page":"2500122","DOI":"10.1002\/smtd.202500122","volume":"9","author":"M Cao","year":"2025","unstructured":"Cao M, Brennan A, Lee CM, Park S-H, Bao G (2025) Deep Learning Based Models for CRISPR\/Cas Off-Target Prediction. Small Methods 9(7):2500122. https:\/\/doi.org\/10.1002\/smtd.202500122","journal-title":"Small Methods"},{"issue":"24","key":"1343_CR20","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1101\/gad.1742908","volume":"22","author":"J Carte","year":"2008","unstructured":"Carte J, Wang R, Li H, Terns RM, Terns MP (2008) Cas6 is an endoribonuclease that generates guide RNAs for invader defense in prokaryotes. Genes Dev 22(24):3489\u20133496","journal-title":"Genes Dev"},{"issue":"1","key":"1343_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/COH.0000000000000600","volume":"15","author":"M Caskey","year":"2020","unstructured":"Caskey M (2020) Broadly neutralizing antibodies for the treatment and prevention of HIV infection. Curr Opin HIV AIDS 15(1):49\u201355","journal-title":"Curr Opin HIV AIDS"},{"issue":"4","key":"1343_CR22","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41591-019-0412-8","volume":"25","author":"M Caskey","year":"2019","unstructured":"Caskey M, Klein F, Nussenzweig MC (2019) Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nat Med 25(4):547\u2013553","journal-title":"Nat Med"},{"key":"1343_CR23","doi-asserted-by":"publisher","unstructured":"Cavazza A, Molina-Est\u00e9vez FJ, Reyes \u00c1P, Ronco V, Naseem A, Malen\u0161ek \u0160, Pe\u010dan P, Santini A, Heredia P, Aguilar-Gonz\u00e1lez A, Boulaiz H, Ni Q, Cortijo-Gutierrez M, Pavlovic K, Herrera I, de la Cerda B, Garcia-Tenorio EM, Richard E, Granados-Principal S, Benabdellah K (2025) Advanced delivery systems for gene editing: a comprehensive review from the GenE-HumDi COST action working group. Mol Therapy Nucleic Acids 36(1). https:\/\/doi.org\/10.1016\/j.omtn.2025.102457","DOI":"10.1016\/j.omtn.2025.102457"},{"issue":"3","key":"1343_CR24","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nbt.2507","volume":"31","author":"SW Cho","year":"2013","unstructured":"Cho SW, Kim S, Kim JM, Kim J-S (2013) Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31(3):230\u2013232","journal-title":"Nat Biotechnol"},{"issue":"7","key":"1343_CR25","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.1128\/jvi.77.7.4449-4456.2003","volume":"77","author":"T Cilliers","year":"2003","unstructured":"Cilliers T, Nhlapo J, Coetzer M, Orlovic D, Ketas T, Olson William C, John M, Trkola P, A., Morris L (2003) The CCR5 and CXCR4 Coreceptors Are Both Used by Human Immunodeficiency Virus Type 1 Primary Isolates from Subtype C. J Virol 77(7):4449\u20134456. https:\/\/doi.org\/10.1128\/jvi.77.7.4449-4456.2003","journal-title":"J Virol"},{"issue":"3","key":"1343_CR26","doi-asserted-by":"publisher","first-page":"e92118","DOI":"10.1371\/journal.pone.0092118","volume":"9","author":"AR Cillo","year":"2014","unstructured":"Cillo AR, Krishnan S, McMahon DK, Mitsuyasu RT, Para MF, Mellors JW (2014) Impact of chemotherapy for HIV-1 related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy. PLoS ONE 9(3):e92118","journal-title":"PLoS ONE"},{"issue":"4","key":"1343_CR27","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41594-022-00756-0","volume":"29","author":"JC Cofsky","year":"2022","unstructured":"Cofsky JC, Soczek KM, Knott GJ, Nogales E, Doudna JA (2022) CRISPR\u2013Cas9 bends and twists DNA to read its sequence. Nat Struct Mol Biol 29(4):395\u2013402. https:\/\/doi.org\/10.1038\/s41594-022-00756-0","journal-title":"Nat Struct Mol Biol"},{"issue":"20","key":"1343_CR28","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1056\/NEJMra1011874","volume":"364","author":"MS Cohen","year":"2011","unstructured":"Cohen MS, Shaw GM, McMichael AJ, Haynes BF (2011) Acute HIV-1 Infection. N Engl J Med 364(20):1943\u20131954. https:\/\/doi.org\/10.1056\/NEJMra1011874","journal-title":"N Engl J Med"},{"issue":"1","key":"1343_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1742-4690-6-111","volume":"6","author":"L Colin","year":"2009","unstructured":"Colin L, Van Lint C (2009) Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 6(1):111","journal-title":"Retrovirology"},{"issue":"1","key":"1343_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2174\/157488408783329913","volume":"3","author":"G D\u2019Andrea","year":"2008","unstructured":"D\u2019Andrea G, Brisdelli F, Bozzi A (2008) AZT: an old drug with new perspectives. Curr Clin Pharmacol 3(1):20\u201337","journal-title":"Curr Clin Pharmacol"},{"issue":"1","key":"1343_CR31","doi-asserted-by":"publisher","first-page":"14413","DOI":"10.1038\/s41598-017-12612-z","volume":"7","author":"W Dampier","year":"2017","unstructured":"Dampier W, Sullivan NT, Chung C-H, Mell JC, Nonnemacher MR, Wigdahl B (2017) Designing broad-spectrum anti-HIV-1 gRNAs to target patient-derived variants. Sci Rep 7(1):14413","journal-title":"Sci Rep"},{"issue":"11","key":"1343_CR32","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1089\/aid.2017.0274","volume":"34","author":"W Dampier","year":"2018","unstructured":"Dampier W, Sullivan NT, Mell JC, Pirrone V, Ehrlich GD, Chung C-H, Allen AG, DeSimone M, Zhong W, Kercher K (2018) Broad-spectrum and personalized guide RNAs for CRISPR\/Cas9 HIV-1 therapeutics. AIDS Res Hum Retroviruses 34(11):950\u2013960","journal-title":"AIDS Res Hum Retroviruses"},{"key":"1343_CR33","doi-asserted-by":"publisher","unstructured":"Darbyshire J, Foulkes M, Peto R, Duncan W, Babiker A, Collins R, Hughes M, Peto TEA, Walker SA (2000) Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults. Cochrane Database Syst Reviews 3. https:\/\/doi.org\/10.1002\/14651858.CD002038","DOI":"10.1002\/14651858.CD002038"},{"issue":"1","key":"1343_CR34","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1038\/s41467-019-10366-y","volume":"10","author":"PK Dash","year":"2019","unstructured":"Dash PK, Kaminski R, Bella R, Su H, Mathews S, Ahooyi TM, Chen C, Mancuso P, Sariyer R, Ferrante P, Donadoni M, Robinson JA, Sillman B, Lin Z, Hilaire JR, Banoub M, Elango M, Gautam N, Mosley RL, Gendelman HE (2019) Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice. Nat Commun 10(1):2753. https:\/\/doi.org\/10.1038\/s41467-019-10366-y","journal-title":"Nat Commun"},{"key":"1343_CR35","unstructured":"Datta P (2016) HIV-1 latency and eradication: past, present and future. Curr HIV Res"},{"issue":"7109","key":"1343_CR36","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature05115","volume":"443","author":"CL Day","year":"2006","unstructured":"Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C (2006) PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443(7109):350\u2013354","journal-title":"Nature"},{"issue":"7408","key":"1343_CR37","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/487439a","volume":"487","author":"SG Deeks","year":"2012","unstructured":"Deeks SG (2012) Shock and kill. Nature 487(7408):439\u2013440","journal-title":"Nature"},{"issue":"7340","key":"1343_CR38","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/nature09886","volume":"471","author":"E Deltcheva","year":"2011","unstructured":"Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirzada ZA, Eckert MR, Vogel J, Charpentier E (2011) CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471(7340):602\u2013607. https:\/\/doi.org\/10.1038\/nature09886","journal-title":"Nature"},{"key":"1343_CR39","doi-asserted-by":"publisher","unstructured":"D\u00e9saulniers K, Ortiz L, Dufour C, Claudel A, Plourde MB, Merindol N, Berthoux L (2020) Editing of the TRIM5 gene decreases the permissiveness of human T lymphocytic cells to HIV-1. Viruses 13(1). https:\/\/doi.org\/10.3390\/v13010024","DOI":"10.3390\/v13010024"},{"issue":"9","key":"1343_CR40","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41564-020-0735-8","volume":"5","author":"A Dharan","year":"2020","unstructured":"Dharan A, Bachmann N, Talley S, Zwikelmaier V, Campbell EM (2020) Nuclear pore blockade reveals that HIV-1 completes reverse transcription and uncoating in the nucleus. Nat Microbiol 5(9):1088\u20131095. https:\/\/doi.org\/10.1038\/s41564-020-0735-8","journal-title":"Nat Microbiol"},{"issue":"2","key":"1343_CR41","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3390\/v4020309","volume":"4","author":"CA Didigu","year":"2012","unstructured":"Didigu CA, Doms RW (2012) Novel approaches to inhibit HIV entry. Viruses 4(2):309\u2013324","journal-title":"Viruses"},{"issue":"9","key":"1343_CR42","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1093\/infdis\/jiv235","volume":"212","author":"K Djawe","year":"2015","unstructured":"Djawe K, Buchacz K, Hsu L, Chen MJ, Selik RM, Rose C, Williams T, Brooks JT, Schwarcz S (2015) Mortality Risk After AIDS-Defining Opportunistic Illness Among HIV-Infected Persons\u2013San Francisco, 1981\u20132012. J Infect Dis 212(9):1366\u20131375. https:\/\/doi.org\/10.1093\/infdis\/jiv235","journal-title":"J Infect Dis"},{"issue":"6213","key":"1343_CR43","doi-asserted-by":"publisher","first-page":"1258096","DOI":"10.1126\/science.1258096","volume":"346","author":"JA Doudna","year":"2014","unstructured":"Doudna JA, Charpentier E (2014) The new frontier of genome engineering with CRISPR-Cas9. Science 346(6213):1258096. https:\/\/doi.org\/10.1126\/science.1258096","journal-title":"Science"},{"issue":"1","key":"1343_CR44","doi-asserted-by":"publisher","first-page":"e0191709","DOI":"10.1371\/journal.pone.0191709","volume":"13","author":"C Dufour","year":"2018","unstructured":"Dufour C, Claudel A, Joubarne N, Merindol N, Maisonnet T, Masroori N, Plourde MB, Berthoux L (2018) Editing of the human TRIM5 gene to introduce mutations with the potential to inhibit HIV-1. PLoS ONE 13(1):e0191709. https:\/\/doi.org\/10.1371\/journal.pone.0191709","journal-title":"PLoS ONE"},{"issue":"1","key":"1343_CR45","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1038\/srep02510","volume":"3","author":"H Ebina","year":"2013","unstructured":"Ebina H, Misawa N, Kanemura Y, Koyanagi Y (2013) Harnessing the CRISPR\/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep 3(1):2510","journal-title":"Sci Rep"},{"key":"1343_CR46","doi-asserted-by":"publisher","unstructured":"Ekoru K, Young EH, Dillon DG, Gurdasani D, Stehouwer N, Faurholt-Jepsen D, Levitt NS, Crowther NJ, Nyirenda M, Njelekela MA, Ramaiya K, Nyan O, Adewole OO, Anastos K, Compostella C, Dave JA, Fourie CM, Friis H, Kruger IM, Sandhu MS (2018) HIV treatment is associated with a two-fold higher probability of raised triglycerides: pooled analyses in 21 023 individuals in sub-Saharan Africa. Glob Health Epidemiol Genom 3. https:\/\/doi.org\/10.1017\/gheg.2018.7","DOI":"10.1017\/gheg.2018.7"},{"issue":"2","key":"1343_CR47","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11904-024-00692-2","volume":"21","author":"EA Ferreira","year":"2024","unstructured":"Ferreira EA, Clements JE, Veenhuis RT (2024) HIV-1 Myeloid Reservoirs - Contributors to Viral Persistence and Pathogenesis. Curr HIV\/AIDS Rep 21(2):62\u201374. https:\/\/doi.org\/10.1007\/s11904-024-00692-2","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"9","key":"1343_CR48","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","volume":"22","author":"JD Finn","year":"2018","unstructured":"Finn JD, Smith AR, Patel MC, Shaw L, Youniss MR, van Heteren J, Dirstine T, Ciullo C, Lescarbeau R, Seitzer J (2018) A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep 22(9):2227\u20132235","journal-title":"Cell Rep"},{"issue":"5","key":"1343_CR49","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/8394","volume":"5","author":"D Finzi","year":"1999","unstructured":"Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C (1999) Latent infection of CD4\u2009+\u2009T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5(5):512\u2013517","journal-title":"Nat Med"},{"issue":"4","key":"1343_CR50","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1056\/NEJM198707233170401","volume":"317","author":"MA Fischl","year":"1987","unstructured":"Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT, Jackson GG, Durack DT, King D (1987) The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex. N Engl J Med 317(4):185\u2013191. https:\/\/doi.org\/10.1056\/NEJM198707233170401","journal-title":"N Engl J Med"},{"issue":"10","key":"1343_CR51","doi-asserted-by":"publisher","first-page":"727","DOI":"10.7326\/0003-4819-112-10-727","volume":"112","author":"MA Fischl","year":"1990","unstructured":"Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, Hardy WD, Dolin R, Powderly WG, Allan JD, Wong B, Merigan TC, McAuliffe VJ, Hyslop NE, Rhame FS, Balfour HH, Spector SA, Volberding P, Pettinelli C, Anderson J (1990) The Safety and Efficacy of Zidovudine (AZT) in the Treatment of Subjects with Mildly Symptomatic Human Immunodeficiency Virus Type 1 (HIV) Infection. Ann Intern Med 112(10):727\u2013737. https:\/\/doi.org\/10.7326\/0003-4819-112-10-727","journal-title":"Ann Intern Med"},{"issue":"2","key":"1343_CR52","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11908-007-0012-5","volume":"9","author":"N Frahm","year":"2007","unstructured":"Frahm N, Brander C (2007) HIV viral diversity and escape from cellular immunity. Curr Infect Dis Rep 9(2):161\u2013166. https:\/\/doi.org\/10.1007\/s11908-007-0012-5","journal-title":"Curr Infect Dis Rep"},{"key":"1343_CR53","doi-asserted-by":"publisher","unstructured":"Francis AC, Marin M, Prellberg MJ, Palermino-Rowland K, Melikyan GB (2020) HIV-1 uncoating and nuclear import precede the completion of reverse transcription in cell lines and in primary macrophages. Viruses 12(11). https:\/\/doi.org\/10.3390\/v12111234","DOI":"10.3390\/v12111234"},{"issue":"3","key":"1343_CR54","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nbt.2808","volume":"32","author":"Y Fu","year":"2014","unstructured":"Fu Y, Sander JD, Reyon D, Cascio VM, Joung JK (2014) Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol 32(3):279\u2013284","journal-title":"Nat Biotechnol"},{"issue":"8","key":"1343_CR55","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/nmeth.2030","volume":"9","author":"T Gaj","year":"2012","unstructured":"Gaj T, Guo J, Kato Y, Sirk SJ, Barbas CF III (2012) Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. Nat Methods 9(8):805\u2013807","journal-title":"Nat Methods"},{"issue":"6718","key":"1343_CR56","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/17130","volume":"397","author":"F Gao","year":"1999","unstructured":"Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, Cummins LB, Arthur LO, Peeters M, Shaw GM, Sharp PM, Hahn BH (1999) Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397(6718):436\u2013441. https:\/\/doi.org\/10.1038\/17130","journal-title":"Nature"},{"issue":"10","key":"1343_CR57","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.1093\/nar\/gkaa226","volume":"48","author":"Z Gao","year":"2020","unstructured":"Gao Z, Fan M, Das AT, Herrera-Carrillo E, Berkhout B (2020) Extinction of all infectious HIV in cell culture by the CRISPR-Cas12a system with only a single crRNA. Nucleic Acids Res 48(10):5527\u20135539. https:\/\/doi.org\/10.1093\/nar\/gkaa226","journal-title":"Nucleic Acids Res"},{"key":"1343_CR58","doi-asserted-by":"publisher","unstructured":"Garcia-Broncano P, Maddali S, Einkauf KB, Jiang C, Gao C, Chevalier J, Chowdhury FZ, Maswabi K, Ajibola G, Moyo S, Mohammed T, Ncube T, Makhema J, Jean-Philippe P, Yu XG, Powis KM, Lockman S, Kuritzkes DR, Shapiro R, Lichterfeld M (2019) Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile. Sci Transl Med 11(520). https:\/\/doi.org\/10.1126\/scitranslmed.aax7350","DOI":"10.1126\/scitranslmed.aax7350"},{"key":"1343_CR59","doi-asserted-by":"publisher","unstructured":"Garrido C, Abad-Fernandez M, Tuyishime M, Pollara JJ, Ferrari G, Soriano-Sarabia N, Margolis DM (2018) Interleukin-15-stimulated natural killer cells clear HIV-1-infected cells following latency reversal ex vivo. J Virol 92(12). https:\/\/doi.org\/10.1128\/jvi.00235-00218","DOI":"10.1128\/jvi.00235-00218"},{"issue":"39","key":"1343_CR60","doi-asserted-by":"publisher","first-page":"E2579","DOI":"10.1073\/pnas.1208507109","volume":"109","author":"G Gasiunas","year":"2012","unstructured":"Gasiunas G, Barrangou R, Horvath P, Siksnys V (2012) Cas9\u2013crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci 109(39):E2579\u2013E2586. https:\/\/doi.org\/10.1073\/pnas.1208507109","journal-title":"Proc Natl Acad Sci"},{"issue":"11","key":"1343_CR61","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1093\/infdis\/jix191","volume":"215","author":"CL Gay","year":"2017","unstructured":"Gay CL, Bosch RJ, Ritz J, Hataye JM, Aga E, Tressler RL, Mason SW, Hwang CK, Grasela DM, Ray N (2017) Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy. J Infect Dis 215(11):1725\u20131733","journal-title":"J Infect Dis"},{"issue":"11","key":"1343_CR62","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41551-017-0158-x","volume":"1","author":"Z Glass","year":"2017","unstructured":"Glass Z, Li Y, Xu Q (2017) Nanoparticles for CRISPR\u2013Cas9 delivery. Nat biomedical Eng 1(11):854\u2013855","journal-title":"Nat biomedical Eng"},{"issue":"3","key":"1343_CR63","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/qai.0000000000002331","volume":"84","author":"A Gori","year":"2020","unstructured":"Gori A, Antinori A, Vergori A, Cossu MV, Menzaghi B, Sterrantino G, Rusconi S, Cattelan AM, Castelli F, Gianotti N, Orofino G, Ripamonti D, Savinelli S, Manzillo E, Santantonio TA, Celesia BM, Cauda R, Maserati R, Monforte d\u2019Arminio, Mancusi A, D (2020) Effectiveness of Switching to Darunavir\/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The STORE Study. J Acquir Immune Defic Syndr 84(3):290\u2013294. https:\/\/doi.org\/10.1097\/qai.0000000000002331","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"1343_CR64","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1189\/jlb.0713368","volume":"95","author":"PR Gorry","year":"2014","unstructured":"Gorry PR, Francella N, Lewin SR, Collman RG (2014) HIV-1 envelope-receptor interactions required for macrophage infection and implications for current HIV-1 cure strategies. J Leukoc Biol 95(1):71\u201381. https:\/\/doi.org\/10.1189\/jlb.0713368","journal-title":"J Leukoc Biol"},{"issue":"10","key":"1343_CR65","doi-asserted-by":"publisher","first-page":"6661","DOI":"10.1073\/pnas.092056199","volume":"99","author":"JA Grobler","year":"2002","unstructured":"Grobler JA, Stillmock K, Hu B, Witmer M, Felock P, Espeseth AS, Wolfe A, Egbertson M, Bourgeois M, Melamed J (2002) Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci 99(10):6661\u20136666","journal-title":"Proc Natl Acad Sci"},{"issue":"7751","key":"1343_CR66","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","volume":"568","author":"RK Gupta","year":"2019","unstructured":"Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, Peppa D, Salgado M, Martinez-Picado J, Nijhuis M, Wensing AM, Lee H (2019) HIV-1 remission following CCR5\u220632\/\u220632 haematopoietic stem-cell transplantation. Nature 568(7751):244\u2013248","journal-title":"Nature"},{"issue":"5","key":"1343_CR67","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1016\/S2352-3018(20)30069-2","volume":"7","author":"RK Gupta","year":"2020","unstructured":"Gupta RK, Peppa D, Hill AL, G\u00e1lvez C, Salgado M, Pace M, McCoy LE, Griffith SA, Thornhill J, Alrubayyi A (2020) Evidence for HIV-1 cure after CCR5\u220632\/\u220632 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report. Lancet HIV 7(5):e340\u2013e347","journal-title":"Lancet HIV"},{"issue":"1","key":"1343_CR68","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s10142-025-01613-1","volume":"25","author":"HM Hassan","year":"2025","unstructured":"Hassan HM, Zubair A, Helal MH, Almagharbeh WT, Elmagzoub RM (2025) New hope and promise with CRISPR-Cas9 technology for the treatment of HIV. Funct Integr Genom 25(1):108. https:\/\/doi.org\/10.1007\/s10142-025-01613-1","journal-title":"Funct Integr Genom"},{"issue":"31","key":"1343_CR69","doi-asserted-by":"publisher","first-page":"11233","DOI":"10.1073\/pnas.0402357101","volume":"101","author":"DJ Hazuda","year":"2004","unstructured":"Hazuda DJ, Anthony NJ, Gomez RP, Jolly SM, Wai JS, Zhuang L, Fisher TE, Embrey M, Guare JP Jr, Egbertson MS (2004) A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci 101(31):11233\u201311238","journal-title":"Proc Natl Acad Sci"},{"key":"1343_CR70","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11904-013-0190-8","volume":"11","author":"AC Hearps","year":"2014","unstructured":"Hearps AC, Martin GE, Rajasuriar R, Crowe SM (2014) Inflammatory co-morbidities in HIV+ individuals: learning lessons from healthy ageing. Curr HIV\/AIDS Rep 11:20\u201334","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"3","key":"1343_CR71","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/bfgp\/elz021","volume":"19","author":"E Herrera-Carrillo","year":"2020","unstructured":"Herrera-Carrillo E, Gao Z, Berkhout B (2020) CRISPR therapy towards an HIV cure. Brief Funct Genomics 19(3):201\u2013208","journal-title":"Brief Funct Genomics"},{"key":"1343_CR72","doi-asserted-by":"publisher","first-page":"103678","DOI":"10.1016\/j.ebiom.2021.103678","volume":"73","author":"J Herskovitz","year":"2021","unstructured":"Herskovitz J, Hasan M, Patel M, Blomberg WR, Cohen JD, Machhi J, Shahjin F, Mosley RL, McMillan J, Kevadiya BD, Gendelman HE (2021) CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination. EBioMedicine 73:103678. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103678","journal-title":"EBioMedicine"},{"key":"1343_CR73","unstructured":"HIGHLEYMAN L (2022) California man appears to be another person cured of HIV after a stem cell transplant. Aidsmap"},{"issue":"6","key":"1343_CR74","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nri2302","volume":"8","author":"F Hladik","year":"2008","unstructured":"Hladik F, McElrath MJ (2008) Setting the stage: host invasion by HIV. Nat Rev Immunol 8(6):447\u2013457. https:\/\/doi.org\/10.1038\/nri2302","journal-title":"Nat Rev Immunol"},{"key":"1343_CR75","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3389\/fimmu.2016.00522","volume":"7","author":"JJ Hong","year":"2016","unstructured":"Hong JJ, Chang K-T, Villinger F (2016) The dynamics of T and B cells in lymph node during chronic HIV infection: TFH and HIV, unhappy dance partners? Front Immunol 7:522","journal-title":"Front Immunol"},{"issue":"12","key":"1343_CR76","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1182\/blood-2006-04-010637","volume":"108","author":"A Hryniewicz","year":"2006","unstructured":"Hryniewicz A, Boasso A, Edghill-Smith Y, Vaccari M, Fuchs D, Venzon D, Nacsa J, Betts MR, Tsai W-P, Heraud J-M (2006) CTLA-4 blockade decreases TGF-\u03b2, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood 108(12):3834\u20133842","journal-title":"Blood"},{"issue":"7","key":"1343_CR77","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S0969-2126(96)00091-3","volume":"4","author":"Y Hsiou","year":"1996","unstructured":"Hsiou Y, Ding J, Das K, Clark Jr A, Hughes S, Arnold E (1996) Structure of unliganded HIV-1 reverse transcriptase at 2.7 \u00c5 resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure 4(7):853\u2013860","journal-title":"Structure"},{"issue":"6","key":"1343_CR78","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.cell.2023.02.030","volume":"186","author":"J Hsu","year":"2023","unstructured":"Hsu J, Van Besien K, Glesby MJ, Pahwa S, Coletti A, Warshaw MG, Petz LD, Moore TB, Chen YH, Pallikkuth S (2023) HIV-1 remission and possible cure in a woman after haplo-cord blood transplant. Cell 186(6):1115\u20131126 e1118","journal-title":"Cell"},{"issue":"12","key":"1343_CR79","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41569-019-0219-9","volume":"16","author":"PY Hsue","year":"2019","unstructured":"Hsue PY, Waters DD (2019) HIV infection and coronary heart disease: mechanisms and management. Nat Rev Cardiol 16(12):745\u2013759. https:\/\/doi.org\/10.1038\/s41569-019-0219-9","journal-title":"Nat Rev Cardiol"},{"key":"1343_CR200","unstructured":"https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/strategic-information\/hiv-data-and-statistics"},{"issue":"31","key":"1343_CR80","doi-asserted-by":"publisher","first-page":"11461","DOI":"10.1073\/pnas.1405186111","volume":"111","author":"W Hu","year":"2014","unstructured":"Hu W, Kaminski R, Yang F, Zhang Y, Cosentino L, Li F, Luo B, Alvarez-Carbonell D, Garcia-Mesa Y, Karn J (2014) RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci 111(31):11461\u201311466","journal-title":"Proc Natl Acad Sci"},{"key":"1343_CR81","doi-asserted-by":"publisher","unstructured":"Hu W, Li Y-J, Zhen C, Wang Y-Y, Huang H-H, Zou J, Zheng Y-Q, Huang G-C, Meng S-R, Jin J-H, Li J, Zhou M-J, Fu Y-L, Zhang P, Li X-Y, Yang T, Wang X-W, Yang X-H, Song J-W, Zhang C (2022) CCL5-secreting virtual memory CD8\u2009+\u2009T cells inversely associate with viral reservoir size in HIV-1\u2009\u2013\u2009infected individuals on antiretroviral therapy [Original Research]. Front Immunol 13\u20132022. https:\/\/doi.org\/10.3389\/fimmu.2022.897569","DOI":"10.3389\/fimmu.2022.897569"},{"issue":"1","key":"1343_CR82","doi-asserted-by":"publisher","first-page":"e1012862","DOI":"10.1371\/journal.ppat.1012862","volume":"21","author":"SW Huang","year":"2025","unstructured":"Huang SW, Briganti L, Annamalai AS, Greenwood J, Shkriabai N, Haney R, Armstrong ML, Wempe MF, Singh SP, Francis AC, Engelman AN, Kvaratskhelia M (2025) The primary mechanism for highly potent inhibition of HIV-1 maturation by lenacapavir. PLoS Pathog 21(1):e1012862. https:\/\/doi.org\/10.1371\/journal.ppat.1012862","journal-title":"PLoS Pathog"},{"issue":"5","key":"1343_CR83","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.celrep.2016.09.080","volume":"17","author":"JF Hultquist","year":"2016","unstructured":"Hultquist JF, Schumann K, Woo JM, Manganaro L, McGregor MJ, Doudna J, Simon V, Krogan NJ, Marson A (2016) A Cas9 Ribonucleoprotein Platform for Functional Genetic Studies of HIV-Host Interactions in Primary Human T Cells. Cell Rep 17(5):1438\u20131452. https:\/\/doi.org\/10.1016\/j.celrep.2016.09.080","journal-title":"Cell Rep"},{"issue":"7","key":"1343_CR84","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa0802905","volume":"360","author":"G H\u00fctter","year":"2009","unstructured":"H\u00fctter G, Nowak D, Mossner M, Ganepola S, M\u00fc\u00dfig A, Allers K, Schneider T, Hofmann J, K\u00fccherer C, Blau O (2009) Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation. N Engl J Med 360(7):692\u2013698","journal-title":"N Engl J Med"},{"key":"1343_CR85","unstructured":"info.NIH.gov, H (2025) FDA-approved HIV medicines. NIH\u2019s Office of AIDS Research. https:\/\/hivinfo.nih.gov\/understanding-hiv\/fact-sheets\/fda-approved-hiv-medicines"},{"issue":"12","key":"1343_CR86","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.1128\/jb.169.12.5429-5433.1987","volume":"169","author":"Y Ishino","year":"1987","unstructured":"Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A (1987) Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol 169(12):5429\u20135433. https:\/\/doi.org\/10.1128\/jb.169.12.5429-5433.1987","journal-title":"J Bacteriol"},{"issue":"4","key":"1343_CR87","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3390\/cancers13040598","volume":"13","author":"V Janelle","year":"2021","unstructured":"Janelle V, Delisle J-S (2021) T-Cell Dysfunction as a Limitation of Adoptive Immunotherapy: Current Concepts and Mitigation Strategies. Cancers 13(4):598. https:\/\/www.mdpi.com\/2072-6694\/13\/4\/598","journal-title":"Cancers"},{"key":"1343_CR88","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.sbi.2015.02.002","volume":"30","author":"F Jiang","year":"2015","unstructured":"Jiang F, Doudna JA (2015) The structural biology of CRISPR-Cas systems. Curr Opin Struct Biol 30:100\u2013111. https:\/\/doi.org\/10.1016\/j.sbi.2015.02.002","journal-title":"Curr Opin Struct Biol"},{"issue":"6096","key":"1343_CR89","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096):816\u2013821. https:\/\/doi.org\/10.1126\/science.1225829","journal-title":"Science"},{"issue":"2","key":"1343_CR91","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1172\/JCI80566","volume":"126","author":"RB Jones","year":"2016","unstructured":"Jones RB, Walker BD (2016) HIV-specific CD8\u2009+\u2009T cells and HIV eradication. J Clin Investig 126(2):455\u2013463","journal-title":"J Clin Investig"},{"issue":"12","key":"1343_CR90","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1084\/jem.20081398","volume":"205","author":"RB Jones","year":"2008","unstructured":"Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, Wong JC, Satkunarajah M, Schweneker M, Chapman JM (2008) Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 205(12):2763\u20132779","journal-title":"J Exp Med"},{"issue":"2","key":"1343_CR92","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jacc.2023.04.050","volume":"82","author":"DK Kalra","year":"2023","unstructured":"Kalra DK, Vorla M, Michos ED, Agarwala A, Virani S, Duell PB, Raal FJ (2023) Dyslipidemia in Human Immunodeficiency Virus Disease: JACC Review Topic of the Week. J Am Coll Cardiol 82(2):171\u2013181. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.050","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1343_CR93","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/gt.2016.41","volume":"23","author":"R Kaminski","year":"2016","unstructured":"Kaminski R, Bella R, Yin C, Otte J, Ferrante P, Gendelman HE, Li H, Booze R, Gordon J, Hu W (2016a) Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study. Gene Ther 23(8):690\u2013695","journal-title":"Gene Ther"},{"issue":"8\u20139","key":"1343_CR94","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/gt.2016.41","volume":"23","author":"R Kaminski","year":"2016","unstructured":"Kaminski R, Bella R, Yin C, Otte J, Ferrante P, Gendelman HE, Li H, Booze R, Gordon J, Hu W, Khalili K (2016b) Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study. Gene Ther 23(8\u20139):690\u2013695. https:\/\/doi.org\/10.1038\/gt.2016.41","journal-title":"Gene Ther"},{"issue":"1","key":"1343_CR95","doi-asserted-by":"publisher","first-page":"31527","DOI":"10.1038\/srep31527","volume":"6","author":"R Kaminski","year":"2016","unstructured":"Kaminski R, Chen Y, Salkind J, Bella R, Young W-b, Ferrante P, Karn J, Malcolm T, Hu W, Khalili K (2016c) Negative feedback regulation of HIV-1 by gene editing strategy. Sci Rep 6(1):31527","journal-title":"Sci Rep"},{"issue":"13","key":"1343_CR96","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00018-017-2479-z","volume":"74","author":"K Khalili","year":"2017","unstructured":"Khalili K, White MK, Jacobson JM (2017) Novel AIDS therapies based on gene editing. Cell Mol Life Sci 74(13):2439\u20132450. https:\/\/doi.org\/10.1007\/s00018-017-2479-z","journal-title":"Cell Mol Life Sci"},{"issue":"11","key":"1343_CR97","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/3293","volume":"4","author":"JM Kilby","year":"1998","unstructured":"Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D (1998) Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4(11):1302\u20131307","journal-title":"Nat Med"},{"issue":"1","key":"1343_CR99","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.chom.2017.12.004","volume":"23","author":"Y Kim","year":"2018","unstructured":"Kim Y, Anderson JL, Lewin SR (2018) Getting the kill into shock and kill: strategies to eliminate latent HIV. Cell Host Microbe 23(1):14\u201326","journal-title":"Cell Host Microbe"},{"key":"1343_CR98","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.3389\/fimmu.2019.02310","volume":"10","author":"GB Kim","year":"2019","unstructured":"Kim GB, Hege K, Riley JL (2019) CAR talk: how cancer-specific CAR T cells can instruct how to build CAR T cells to cure HIV. Front Immunol 10:2310","journal-title":"Front Immunol"},{"key":"1343_CR100","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jbiotec.2018.08.007","volume":"284","author":"ML Kimberland","year":"2018","unstructured":"Kimberland ML, Hou W, Alfonso-Pecchio A, Wilson S, Rao Y, Zhang S, Lu Q (2018) Strategies for controlling CRISPR\/Cas9 off-target effects and biological variations in mammalian genome editing experiments. J Biotechnol 284:91\u2013101","journal-title":"J Biotechnol"},{"key":"1343_CR101","doi-asserted-by":"publisher","unstructured":"Kirchhoff F (2018) HIV Life Cycle: Overview. In TJ Hope, DD Richman, & M Stevenson (Eds.), Encyclopedia of AIDS (pp. 722\u2013730). Springer New York. https:\/\/doi.org\/10.1007\/978-1-4939-7101-5_60","DOI":"10.1007\/978-1-4939-7101-5_60"},{"issue":"6405","key":"1343_CR102","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1126\/science.aat5011","volume":"361","author":"GJ Knott","year":"2018","unstructured":"Knott GJ, Doudna JA (2018) CRISPR-Cas guides the future of genetic engineering. Science 361(6405):866\u2013869. https:\/\/doi.org\/10.1126\/science.aat5011","journal-title":"Science"},{"issue":"7603","key":"1343_CR103","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR (2016) Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533(7603):420\u2013424. https:\/\/doi.org\/10.1038\/nature17946","journal-title":"Nature"},{"issue":"2","key":"1343_CR104","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S2055-6640(20)30490-8","volume":"1","author":"DA Kulpa","year":"2015","unstructured":"Kulpa DA, Chomont N (2015) HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide? J virus eradication 1(2):59\u201366","journal-title":"J virus eradication"},{"issue":"2","key":"1343_CR105","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/1750743X.2025.2460965","volume":"17","author":"T Laeremans","year":"2025","unstructured":"Laeremans T, Janssens A, Aerts JL (2025) From natural defenders to therapeutic warriors: NK cells in HIV immunotherapy. Immunotherapy 17(2):133\u2013145. https:\/\/doi.org\/10.1080\/1750743X.2025.2460965","journal-title":"Immunotherapy"},{"issue":"1","key":"1343_CR106","doi-asserted-by":"publisher","first-page":"41968","DOI":"10.1038\/srep41968","volume":"7","author":"RJ Lebbink","year":"2017","unstructured":"Lebbink RJ, de Jong DC, Wolters F, Kruse EM, van Ham PM, Wiertz EJ, Nijhuis M (2017) A combinational CRISPR\/Cas9 gene-editing approach can halt HIV replication and prevent viral escape. Sci Rep 7(1):41968","journal-title":"Sci Rep"},{"key":"1343_CR107","doi-asserted-by":"publisher","unstructured":"Lee H, Rho WY, Kim YH, Chang H, Jun BH (2025) CRISPR-Cas9 gene therapy: non-viral delivery and stimuli-responsive nanoformulations. Molecules 30(3). https:\/\/doi.org\/10.3390\/molecules30030542","DOI":"10.3390\/molecules30030542"},{"issue":"10","key":"1343_CR108","doi-asserted-by":"publisher","first-page":"e1006613","DOI":"10.1371\/journal.ppat.1006613","volume":"13","author":"RS Leibman","year":"2017","unstructured":"Leibman RS, Richardson MW, Ellebrecht CT, Maldini CR, Glover JA, Secreto AJ, Kulikovskaya I, Lacey SF, Akkina SR, Yi Y (2017) Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. PLoS Pathog 13(10):e1006613","journal-title":"PLoS Pathog"},{"issue":"1","key":"1343_CR109","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/QAI.0b013e318134257a","volume":"46","author":"C Lewden","year":"2007","unstructured":"Lewden C, Ch\u00eane G, Morlat P, Raffi F, Dupon M, Dellamonica P, Pellegrin J-L, Katlama C, Dabis F, Leport C (2007) HIV-infected adults with a CD4 cell count greater than 500 cells\/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. JAIDS J Acquir Immune Defic Syndr 46(1):72\u201377","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"1343_CR111","doi-asserted-by":"crossref","unstructured":"Li Y (2022) A beloved bioinformatician buddy\u2014in memory of professor Weimin Zhu, vol 20. Oxford University Press, pp 1037\u20131039","DOI":"10.1016\/j.gpb.2022.12.006"},{"key":"1343_CR110","doi-asserted-by":"publisher","first-page":"108561","DOI":"10.1016\/j.biotechadv.2025.108561","volume":"81","author":"X-H Li","year":"2025","unstructured":"Li X-H, Lu H-Z, Yao J-B, Zhang C, Shi T-Q, Huang H (2025) Recent advances in the application of CRISPR\/Cas-based gene editing technology in Filamentous Fungi. Biotechnol Adv 81:108561. https:\/\/doi.org\/10.1016\/j.biotechadv.2025.108561","journal-title":"Biotechnol Adv"},{"issue":"1","key":"1343_CR112","doi-asserted-by":"publisher","first-page":"6413","DOI":"10.1038\/ncomms7413","volume":"6","author":"H-K Liao","year":"2015","unstructured":"Liao H-K, Gu Y, Diaz A, Marlett J, Takahashi Y, Li M, Suzuki K, Xu R, Hishida T, Chang C-J (2015) Use of the CRISPR\/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat Commun 6(1):6413","journal-title":"Nat Commun"},{"issue":"10","key":"1343_CR118","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1007\/s12033-014-9768-7","volume":"56","author":"Y Liu","year":"2014","unstructured":"Liu Y, Zhou J, Pan JA, Mabiala P, Guo D (2014) A novel approach to block HIV-1 coreceptor CXCR4 in non-toxic manner. Mol Biotechnol 56(10):890\u2013902. https:\/\/doi.org\/10.1007\/s12033-014-9768-7","journal-title":"Mol Biotechnol"},{"issue":"13","key":"1343_CR115","doi-asserted-by":"publisher","first-page":"6685","DOI":"10.1128\/JVI.00474-15","volume":"89","author":"L Liu","year":"2015","unstructured":"Liu L, Patel B, Ghanem MH, Bundoc V, Zheng Z, Morgan RA, Rosenberg SA, Dey B, Berger EA (2015) Novel CD4-based bispecific chimeric antigen receptor designed for enhanced anti-HIV potency and absence of HIV entry receptor activity. J Virol 89(13):6685\u20136694","journal-title":"J Virol"},{"issue":"1\u20132","key":"1343_CR114","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cell.2016.12.031","volume":"168","author":"L Liu","year":"2017","unstructured":"Liu L, Li X, Wang J, Wang M, Chen P, Yin M, Li J, Sheng G, Wang Y (2017) Two Distant Catalytic Sites Are Responsible for C2c2 RNase Activities. Cell 168(1\u20132):121\u2013134e112. https:\/\/doi.org\/10.1016\/j.cell.2016.12.031","journal-title":"Cell"},{"issue":"1","key":"1343_CR117","doi-asserted-by":"publisher","first-page":"8573","DOI":"10.1038\/s41598-018-26894-4","volume":"8","author":"S Liu","year":"2018","unstructured":"Liu S, Wang Q, Yu X, Li Y, Guo Y, Liu Z, Sun F, Hou W, Li C, Wu L, Guo D, Chen S (2018) HIV-1 inhibition in cells with CXCR4 mutant genome created by CRISPR-Cas9 and piggyBac recombinant technologies. Sci Rep 8(1):8573. https:\/\/doi.org\/10.1038\/s41598-018-26894-4","journal-title":"Sci Rep"},{"issue":"1","key":"1343_CR119","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13578-020-00444-w","volume":"10","author":"Z Liu","year":"2020","unstructured":"Liu Z, Liang J, Chen S, Wang K, Liu X, Liu B, Xia Y, Guo M, Zhang X, Sun G, Tian G (2020) Genome editing of CCR5 by AsCpf1 renders CD4\u2009+\u2009T cells resistance to HIV-1 infection. Cell bioscience 10(1):85. https:\/\/doi.org\/10.1186\/s13578-020-00444-w","journal-title":"Cell bioscience"},{"issue":"3","key":"1343_CR116","doi-asserted-by":"publisher","first-page":"e12025","DOI":"10.1002\/bmm2.12025","volume":"1","author":"Q Liu","year":"2023","unstructured":"Liu Q, Yang J, Xing Y, Zhao Y, Liu Y (2023) Development of delivery strategies for CRISPR-Cas9 genome editing. BMEMat 1(3):e12025. https:\/\/doi.org\/10.1002\/bmm2.12025","journal-title":"BMEMat"},{"issue":"6","key":"1343_CR113","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1016\/j.ymthe.2025.03.026","volume":"33","author":"D Liu","year":"2025","unstructured":"Liu D, Cao D, Han R (2025) Recent advances in therapeutic gene-editing technologies. Mol Ther 33(6):2619\u20132644. https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.026","journal-title":"Mol Ther"},{"issue":"6288","key":"1343_CR120","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1126\/science.aaf1279","volume":"352","author":"C-L Lu","year":"2016","unstructured":"Lu C-L, Murakowski DK, Bournazos S, Schoofs T, Sarkar D, Halper-Stromberg A, Horwitz JA, Nogueira L, Golijanin J, Gazumyan A (2016) Enhanced clearance of HIV-1\u2013infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 352(6288):1001\u20131004","journal-title":"Science"},{"issue":"7","key":"1343_CR121","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJM199802123380706","volume":"338","author":"AD Luster","year":"1998","unstructured":"Luster AD (1998) Chemokines \u2014 Chemotactic Cytokines That Mediate Inflammation. N Engl J Med 338(7):436\u2013445. https:\/\/doi.org\/10.1056\/NEJM199802123380706","journal-title":"N Engl J Med"},{"issue":"1","key":"1343_CR122","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1186\/s12879-022-07739-y","volume":"22","author":"P Maggi","year":"2022","unstructured":"Maggi P, De Socio GV, Menzaghi B, Molteni C, Squillace N, Taramasso L, Guastavigna M, Gamboni G, Madeddu G, Vichi F, Cascio A, Sarchi E, Pellican\u00f2 G, Martinelli CV, Celesia BM, Valsecchi L, Gulminetti R, Cenderello G, Parisini A, Bonfanti P (2022) Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity? BMC Infect Dis 22(1):745. https:\/\/doi.org\/10.1186\/s12879-022-07739-y","journal-title":"BMC Infect Dis"},{"key":"1343_CR123","doi-asserted-by":"publisher","unstructured":"Magro G, Calistri A, Parolin C (2021) Targeting and understanding HIV latency: The CRISPR system against the provirus. Pathogens 10(10). https:\/\/doi.org\/10.3390\/pathogens10101257","DOI":"10.3390\/pathogens10101257"},{"issue":"1","key":"1343_CR124","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12981-025-00734-8","volume":"22","author":"S Mahomed","year":"2025","unstructured":"Mahomed S, Pillay K, Hassan-Moosa R, Galv\u00e3o BPGV, Burgers WA, Moore PL, Rose-Abrahams M, Williamson C, Garrett N (2025) Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV \u2013 a review. AIDS Res Therapy 22(1):44. https:\/\/doi.org\/10.1186\/s12981-025-00734-8","journal-title":"AIDS Res Therapy"},{"issue":"1","key":"1343_CR125","doi-asserted-by":"publisher","first-page":"6065","DOI":"10.1038\/s41467-020-19821-7","volume":"11","author":"P Mancuso","year":"2020","unstructured":"Mancuso P, Chen C, Kaminski R, Gordon J, Liao S, Robinson JA, Smith MD, Liu H, Sariyer IK, Sariyer R, Peterson TA, Donadoni M, Williams JB, Siddiqui S, Bunnell BA, Ling B, MacLean AG, Burdo TH, Khalili K (2020) CRISPR based editing of SIV proviral DNA in ART treated non-human primates. Nat Commun 11(1):6065. https:\/\/doi.org\/10.1038\/s41467-020-19821-7","journal-title":"Nat Commun"},{"issue":"5909","key":"1343_CR126","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1126\/science.1165771","volume":"322","author":"LA Marraffini","year":"2008","unstructured":"Marraffini LA, Sontheimer EJ (2008) CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. Science 322(5909):1843\u20131845. https:\/\/doi.org\/10.1126\/science.1165771","journal-title":"Science"},{"issue":"7280","key":"1343_CR127","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature08703","volume":"463","author":"LA Marraffini","year":"2010","unstructured":"Marraffini LA, Sontheimer EJ (2010) Self versus non-self discrimination during CRISPR RNA-directed immunity. Nature 463(7280):568\u2013571","journal-title":"Nature"},{"issue":"22","key":"1343_CR128","doi-asserted-by":"publisher","first-page":"12373","DOI":"10.1128\/jvi.77.22.12373-12377.2003","volume":"77","author":"J Martin-Serrano","year":"2003","unstructured":"Martin-Serrano J, Bieniasz PD (2003) A bipartite late-budding domain in human immunodeficiency virus type 1. J Virol 77(22):12373\u201312377. https:\/\/doi.org\/10.1128\/jvi.77.22.12373-12377.2003","journal-title":"J Virol"},{"issue":"7793","key":"1343_CR129","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41586-020-1946-0","volume":"578","author":"JB McBrien","year":"2020","unstructured":"McBrien JB, Mavigner M, Franchitti L, Smith SA, White E, Tharp GK, Walum H, Busman-Sahay K, Aguilera-Sandoval CR, Thayer WO (2020) Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8\u2009+\u2009cells. Nature 578(7793):154\u2013159","journal-title":"Nature"},{"issue":"11","key":"1343_CR130","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIRCRESAHA.124.323948","volume":"134","author":"K McCutcheon","year":"2024","unstructured":"McCutcheon K, Nqebelele U, Murray L, Thomas TS, Mpanya D, Tsabedze N (2024) Cardiac and Renal Comorbidities in Aging People Living With HIV. Circul Res 134(11):1636\u20131660. https:\/\/doi.org\/10.1161\/CIRCRESAHA.124.323948","journal-title":"Circul Res"},{"key":"1343_CR131","doi-asserted-by":"crossref","unstructured":"Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L (2011) Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 7(1):e1001251","DOI":"10.1371\/journal.ppat.1001251"},{"key":"1343_CR132","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1097\/00126334-200103011-00005","volume":"26","author":"V Miller","year":"2001","unstructured":"Miller V (2001) Resistance to protease inhibitors. JAIDS J Acquir Immune Defic Syndr 26:S34\u2013S50","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"3","key":"1343_CR133","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/COH.0b013e32835ef0a1","volume":"8","author":"R Mitsuyasu","year":"2013","unstructured":"Mitsuyasu R (2013) Curing HIV: lessons from cancer therapy. Curr Opin HIV AIDS 8(3):224\u2013229","journal-title":"Curr Opin HIV AIDS"},{"key":"1343_CR134","doi-asserted-by":"publisher","unstructured":"Mohamed H, Gurrola T, Berman R, Collins M, Sariyer IK, Nonnemacher MR, Wigdahl B (2022) Targeting CCR5 as a component of an HIV-1 therapeutic strategy [Review]. Front Immunol 12. https:\/\/doi.org\/10.3389\/fimmu.2021.816515","DOI":"10.3389\/fimmu.2021.816515"},{"key":"1343_CR135","doi-asserted-by":"publisher","unstructured":"Mohsenpour M, Zamani K, Amirian R, Shariatpanahi ME (2025) Bioinformatics tools developed for genome editing studies. In K. Sharma (Ed.), omics and genome editing: revolution in crop improvement for sustainable agriculture (pp. 191\u2013205). Springer Nature Switzerland. https:\/\/doi.org\/10.1007\/978-3-031-81639-0_13","DOI":"10.1007\/978-3-031-81639-0_13"},{"issue":"1","key":"1343_CR136","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/imr.12502","volume":"275","author":"S Moir","year":"2017","unstructured":"Moir S, Fauci AS (2017) B-cell responses to HIV infection. Immunol Rev 275(1):33\u201348","journal-title":"Immunol Rev"},{"issue":"2","key":"1343_CR137","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s00239-004-0046-3","volume":"60","author":"FJ Mojica","year":"2005","unstructured":"Mojica FJ, D\u00edez-Villase\u00f1or C, Garc\u00eda-Mart\u00ednez J, Soria E (2005) Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol 60(2):174\u2013182. https:\/\/doi.org\/10.1007\/s00239-004-0046-3","journal-title":"J Mol Evol"},{"key":"1343_CR138","doi-asserted-by":"crossref","unstructured":"Moso MA, Roche M, Cevaal PM, Lewin SR (2025) CRISPR\/Cas9 for achieving postintervention HIV control. Curr Opin HIV AIDS, 20(5). https:\/\/journals.lww.com\/co-hivandaids\/fulltext\/2025\/09000\/crispr_cas9_for_achieving_postintervention_hiv.3.aspx","DOI":"10.1097\/COH.0000000000000963"},{"key":"1343_CR139","doi-asserted-by":"publisher","unstructured":"Mota TM, McCann CD, Danesh A, Huang S-H, Magat DB, Ren Y, Leyre L, Bui TD, Rohwetter TM, Kovacs CM (2020) Integrated assessment of viral transcription, antigen presentation, and CD8\u2009+\u2009T cell function reveals multiple limitations of class I-selective histone deacetylase inhibitors during HIV-1 latency reversal. J Virol 94(9): 01845\u2009\u2013\u200901819. https:\/\/doi.org\/10.1128\/jvi","DOI":"10.1128\/jvi"},{"key":"1343_CR140","doi-asserted-by":"crossref","unstructured":"Mulanovich VE, Desai PA, Popat UR (2016) Allogeneic stem cell transplantation for HIV-positive patients with hematologic malignancies. Aids 30(17). https:\/\/journals.lww.com\/aidsonline\/fulltext\/2016\/11130\/allogeneic_stem_cell_transplantation_for.11.aspx","DOI":"10.1097\/QAD.0000000000001240"},{"issue":"2","key":"1343_CR141","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/med4.70016","volume":"3","author":"P Nagendran","year":"2025","unstructured":"Nagendran P, Murugesan G, Natarajan J (2025) Anticipating On-Target and Off-Target Effects of CRISPR\/Cas9 Genome Editing Via a Feedforward Neural Network Model. Med Adv 3(2):88\u201396. https:\/\/doi.org\/10.1002\/med4.70016","journal-title":"Med Adv"},{"issue":"2","key":"1343_CR142","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.molcel.2021.12.026","volume":"82","author":"TS Nambiar","year":"2022","unstructured":"Nambiar TS, Baudrier L, Billon P, Ciccia A (2022) CRISPR-based genome editing through the lens of DNA repair. Mol Cell 82(2):348\u2013388. https:\/\/doi.org\/10.1016\/j.molcel.2021.12.026","journal-title":"Mol Cell"},{"issue":"523","key":"1343_CR144","doi-asserted-by":"publisher","first-page":"eaax4077","DOI":"10.1126\/scitranslmed.aax4077","volume":"11","author":"S Nguyen","year":"2019","unstructured":"Nguyen S, Deleage C, Darko S, Ransier A, Truong DP, Agarwal D, Japp AS, Wu VH, Kuri-Cervantes L, Abdel-Mohsen M, Rio Estrada D, Ablanedo-Terrazas PM, Gostick Y, Hoxie E, Zhang JA, Naji NR, Reyes-Ter\u00e1n A, Estes G, Price JD, Betts DA, M. R (2019) Elite control of HIV is associated with distinct functional and transcriptional signatures in lymphoid tissue CD8\u2009<\u2009sup>+\u2009T cells. Sci Transl Med 11(523):eaax4077. https:\/\/doi.org\/10.1126\/scitranslmed.aax4077","journal-title":"Sci Transl Med"},{"key":"1343_CR143","doi-asserted-by":"publisher","unstructured":"Nguyen H, Wilson H, Jayakumar S, Kulkarni V, Kulkarni S (2021) Efficient inhibition of HIV using CRISPR\/Cas13d nuclease system. Viruses 13(9). https:\/\/doi.org\/10.3390\/v13091850","DOI":"10.3390\/v13091850"},{"key":"1343_CR146","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.coviro.2019.07.011","volume":"38","author":"A Olson","year":"2019","unstructured":"Olson A, Basukala B, Wong WW, Henderson AJ (2019) Targeting HIV-1 proviral transcription. Curr Opin Virol 38:89\u201396. https:\/\/doi.org\/10.1016\/j.coviro.2019.07.011","journal-title":"Curr Opin Virol"},{"key":"1343_CR145","doi-asserted-by":"publisher","unstructured":"Olson A, Basukala B, Lee S, Gagne M, Wong WW, Henderson AJ (2020) Targeted chromatinization and repression of HIV-1 provirus transcription with repurposed CRISPR\/Cas9. Viruses 12(10). https:\/\/doi.org\/10.3390\/v12101154","DOI":"10.3390\/v12101154"},{"key":"1343_CR147","doi-asserted-by":"publisher","unstructured":"Ophinni Y, Miki S, Hayashi Y, Kameoka M (2020) Multiplexed tat-targeting CRISPR-Cas9 protects T cells from acute HIV-1 infection with inhibition of viral escape. Viruses 12(11). https:\/\/doi.org\/10.3390\/v12111223","DOI":"10.3390\/v12111223"},{"key":"1343_CR148","doi-asserted-by":"crossref","unstructured":"Ousterout DG, Gersbach CA (2016) The development of TALE nucleases for biotechnology. TALENs: Methods Protocols 27\u201342","DOI":"10.1007\/978-1-4939-2932-0_3"},{"issue":"7925","key":"1343_CR149","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41586-022-05114-0","volume":"609","author":"M Pacesa","year":"2022","unstructured":"Pacesa M, Loeff L, Querques I, Muckenfuss LM, Sawicka M, Jinek M (2022) R-loop formation and conformational activation mechanisms of Cas9. Nature 609(7925):191\u2013196. https:\/\/doi.org\/10.1038\/s41586-022-05114-0","journal-title":"Nature"},{"issue":"5","key":"1343_CR150","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.cell.2024.01.042","volume":"187","author":"M Pacesa","year":"2024","unstructured":"Pacesa M, Pelea O, Jinek M (2024) Past, present, and future of CRISPR genome editing technologies. Cell 187(5):1076\u20131100. https:\/\/doi.org\/10.1016\/j.cell.2024.01.042","journal-title":"Cell"},{"key":"1343_CR151","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3389\/fimmu.2017.01380","volume":"8","author":"S Pallikkuth","year":"2017","unstructured":"Pallikkuth S, De Armas L, Rinaldi S, Pahwa S (2017) T follicular helper cells and B cell dysfunction in aging and HIV-1 infection. Front Immunol 8:1380","journal-title":"Front Immunol"},{"issue":"sup1","key":"1343_CR152","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1185\/03007999909114096","volume":"15","author":"E Papadopulos-eleopulos","year":"1999","unstructured":"Papadopulos-eleopulos E, Turner VF, Papadimitriou JM, Causer D, Alphonso H, Miller T (1999) A Critical Analysis of the Pharmacology of AZT and its Use in AIDS. Curr Med Res Opin 15(sup1):S1\u2013S45. https:\/\/doi.org\/10.1185\/03007999909114096","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"1343_CR153","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1006\/viro.1993.1328","volume":"194","author":"J Park","year":"1993","unstructured":"Park J, Morrow CD (1993) Mutations in the protease gene of human immunodeficiency virus type 1 affect release and stability of virus particles. Virology 194(2):843\u2013850","journal-title":"Virology"},{"issue":"3","key":"1343_CR154","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.idc.2014.06.001","volume":"28","author":"AK Pau","year":"2014","unstructured":"Pau AK, George JM (2014) Antiretroviral therapy: current drugs. Infect Dis Clin North Am 28(3):371\u2013402. https:\/\/doi.org\/10.1016\/j.idc.2014.06.001","journal-title":"Infect Dis Clin North Am"},{"issue":"3","key":"1343_CR155","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/hiv.13557","volume":"25","author":"S Payra","year":"2024","unstructured":"Payra S, Manjhi PK, Singh S, Kumar R, Singh SK, Kumar A, Maharshi V (2024) HIV cure: Are we going to make history? HIV Med 25(3):322\u2013331. https:\/\/doi.org\/10.1111\/hiv.13557","journal-title":"HIV Med"},{"issue":"5403","key":"1343_CR156","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1126\/science.283.5403.845","volume":"283","author":"A Peled","year":"1999","unstructured":"Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, Nagler A, Ben-Hur H, Many A, Shultz L (1999) Dependence of human stem cell engraftment and repopulation of NOD\/SCID mice on CXCR4. Science 283(5403):845\u2013848","journal-title":"Science"},{"issue":"1","key":"1343_CR157","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41392-023-01514-4","volume":"8","author":"D Peterhoff","year":"2023","unstructured":"Peterhoff D (2023) New case of HIV cure: joined forces of haploidentical stem cells and HLA-mismatched cord blood. Signal Transduct Target Therapy 8(1):241","journal-title":"Signal Transduct Target Therapy"},{"issue":"10","key":"1343_CR158","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1084\/jem.20061496","volume":"203","author":"C Petrovas","year":"2006","unstructured":"Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, Adams WC, Precopio ML, Schacker T, Roederer M, Douek DC (2006) PD-1 is a regulator of virus-specific CD8\u2009+\u2009T cell survival in HIV infection. J Exp Med 203(10):2281\u20132292","journal-title":"J Exp Med"},{"issue":"8","key":"1343_CR159","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1592\/phco.26.8.1111","volume":"26","author":"FJ Piacenti","year":"2006","unstructured":"Piacenti FJ (2006) An Update and Review of Antiretroviral Therapy. Pharmacotherapy: J Hum Pharmacol Drug Therapy 26(8):1111\u20131133. https:\/\/doi.org\/10.1592\/phco.26.8.1111","journal-title":"Pharmacotherapy: J Hum Pharmacol Drug Therapy"},{"issue":"4","key":"1343_CR160","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1365-2567.2012.03592.x","volume":"136","author":"AC Picton","year":"2012","unstructured":"Picton AC, Shalekoff S, Paximadis M, Tiemessen CT (2012) Marked differences in CCR5 expression and activation levels in two South African populations. Immunology 136(4):397\u2013407","journal-title":"Immunology"},{"issue":"8","key":"1343_CR161","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3390\/v12080885","volume":"12","author":"DO Pinto","year":"2020","unstructured":"Pinto DO, DeMarino C, Vo TT, Cowen M, Kim Y, Pleet ML, Barclay RA, Hooten N, Evans N, M. K., Heredia A (2020) Low-level ionizing radiation induces selective killing of HIV-1-infected cells with reversal of cytokine induction using mTOR inhibitors. Viruses 12(8):885","journal-title":"Viruses"},{"issue":"6831","key":"1343_CR162","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/35073639","volume":"410","author":"P Piot","year":"2001","unstructured":"Piot P, Bartos M, Ghys PD, Walker N, Schwartl\u00e4nder B (2001) The global impact of HIV\/AIDS. Nature 410(6831):968\u2013973","journal-title":"Nature"},{"issue":"6","key":"1343_CR163","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S1368-7646(02)00123-1","volume":"5","author":"ME Qui\u00f1ones-Mateu","year":"2002","unstructured":"Qui\u00f1ones-Mateu ME, Arts EJ (2002) Fitness of drug resistant HIV-1: methodology and clinical implications. Drug Resist Updates 5(6):224\u2013233","journal-title":"Drug Resist Updates"},{"key":"1343_CR164","doi-asserted-by":"crossref","unstructured":"Rauf MA, Rao A, Sivasoorian SS, Iyer AK (2025) Nanotechnology-based delivery of CRISPR\/Cas9 for cancer treatment: a comprehensive review. Cells 14(15)","DOI":"10.3390\/cells14151136"},{"issue":"6831","key":"1343_CR165","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/35073673","volume":"410","author":"DD Richman","year":"2001","unstructured":"Richman DD (2001) HIV chemotherapy. Nature 410(6831):995\u20131001","journal-title":"Nature"},{"issue":"4","key":"1343_CR166","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/QCO.0000000000001022","volume":"37","author":"PG Rubinstein","year":"2024","unstructured":"Rubinstein PG, Galvez C, Ambinder RF (2024) Hematopoietic stem cell transplantation and cellular therapy in persons living with HIV. Curr Opin Infect Dis 37(4):254\u2013263","journal-title":"Curr Opin Infect Dis"},{"issue":"1\u20132","key":"1343_CR167","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.virol.2013.08.002","volume":"446","author":"GK Sahu","year":"2013","unstructured":"Sahu GK, Sango K, Selliah N, Ma Q, Skowron G, Junghans RP (2013) Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells. Virology 446(1\u20132):268\u2013275","journal-title":"Virology"},{"issue":"1","key":"1343_CR168","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/ijstd.IJSTD_112_15","volume":"40","author":"M Sankaranantham","year":"2019","unstructured":"Sankaranantham M (2019) HIV\u2013Is a cure possible? Indian J sexually transmitted Dis AIDS 40(1):1\u20135","journal-title":"Indian J sexually transmitted Dis AIDS"},{"issue":"2","key":"1343_CR169","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1128\/JVI.02036-08","volume":"83","author":"DN Sather","year":"2009","unstructured":"Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self S, Kalams S (2009) Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 83(2):757\u2013769","journal-title":"J Virol"},{"issue":"4","key":"1343_CR170","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrneurol.2016.27","volume":"12","author":"D Saylor","year":"2016","unstructured":"Saylor D, Dickens AM, Sacktor N, Haughey N, Slusher B, Pletnikov M, Mankowski JL, Brown A, Volsky DJ, McArthur JC (2016) HIV-associated neurocognitive disorder\u2014pathogenesis and prospects for treatment. Nat Reviews Neurol 12(4):234\u2013248","journal-title":"Nat Reviews Neurol"},{"key":"1343_CR171","doi-asserted-by":"publisher","unstructured":"Schuitemaker H, van \u2018t Wout AB, Lusso P (2011) Clinical significance of HIV-1 coreceptor usage. J Transl Med 9(Suppl 1):S5. https:\/\/doi.org\/10.1186\/1479-5876-9-s1-s5","DOI":"10.1186\/1479-5876-9-s1-s5"},{"key":"1343_CR172","doi-asserted-by":"publisher","unstructured":"Seijas A, Cora D, Novo M, Al-Soufi W, S\u00e1nchez L, Arana \u00c1, J (2025) CRISPR\/Cas9 Delivery Systems to Enhance Gene Editing Efficiency. Int J Mol Sci 26(9). https:\/\/doi.org\/10.3390\/ijms26094420","DOI":"10.3390\/ijms26094420"},{"issue":"10","key":"1343_CR173","doi-asserted-by":"publisher","first-page":"609","DOI":"10.20452\/pamw.4357","volume":"128","author":"L Seyler","year":"2018","unstructured":"Seyler L, Lacor P, Allard SD (2018) Current challenges in the treatment of HIV. Pol Arch Intern Med 128(10):609\u2013616","journal-title":"Pol Arch Intern Med"},{"issue":"3","key":"1343_CR174","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.immuni.2012.01.014","volume":"36","author":"L Shan","year":"2012","unstructured":"Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang H-C, Zhang H, Margolick JB, Blankson JN, Siliciano RF (2012) Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36(3):491\u2013501","journal-title":"Immunity"},{"key":"1343_CR175","doi-asserted-by":"crossref","unstructured":"Siangphoe U, Archer KJ, Nguyen C, Lee KR (2020) Associations of antiretroviral therapy and comorbidities with neurocognitive outcomes in HIV-1-infected patients. Aids 34(6). https:\/\/journals.lww.com\/aidsonline\/fulltext\/2020\/05010\/associations_of_antiretroviral_therapy_and.10.aspx","DOI":"10.1097\/QAD.0000000000002491"},{"issue":"2, Supplement 2","key":"1343_CR176","doi-asserted-by":"publisher","first-page":"S582","DOI":"10.1067\/mai.2003.91","volume":"111","author":"JW Sleasman","year":"2003","unstructured":"Sleasman JW, Goodenow MM (2003) 13. HIV-1 infection. J Allergy Clin Immunol 111(2, Supplement 2):S582\u2013S592. https:\/\/doi.org\/10.1067\/mai.2003.91","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1343_CR177","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1146\/annurev-immunol-080219-023629","volume":"38","author":"KE Stephenson","year":"2020","unstructured":"Stephenson KE, Wagh K, Korber B, Barouch DH (2020) Vaccines and broadly neutralizing antibodies for HIV-1 prevention. Annu Rev Immunol 38(1):673\u2013703","journal-title":"Annu Rev Immunol"},{"issue":"7490","key":"1343_CR178","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nature13011","volume":"507","author":"SH Sternberg","year":"2014","unstructured":"Sternberg SH, Redding S, Jinek M, Greene EC, Doudna JA (2014) DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature 507(7490):62\u201367. https:\/\/doi.org\/10.1038\/nature13011","journal-title":"Nature"},{"issue":"3","key":"1343_CR179","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1006\/jmbi.1994.1665","volume":"243","author":"C Tantillo","year":"1994","unstructured":"Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, Pauwels R, Andries K, Janssen PA, Arnold E (1994) Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase: implications for mechanisms of drug inhibition and resistance. J Mol Biol 243(3):369\u2013387","journal-title":"J Mol Biol"},{"issue":"4","key":"1343_CR180","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.4049\/jimmunol.179.4.2097","volume":"179","author":"C Tomescu","year":"2007","unstructured":"Tomescu C, Chehimi J, Maino VC, Montaner LJ (2007) NK cell lysis of HIV-1-infected autologous CD4 primary T cells: requirement for IFN-mediated NK activation by plasmacytoid dendritic cells. J Immunol 179(4):2097\u20132104. https:\/\/doi.org\/10.4049\/jimmunol.179.4.2097","journal-title":"J Immunol"},{"issue":"10","key":"1343_CR181","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/nm1482","volume":"12","author":"L Trautmann","year":"2006","unstructured":"Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, Boulassel M-R, Delwart E, Sepulveda H, Balderas RS (2006) Upregulation of PD-1 expression on HIV-specific CD8\u2009+\u2009T cells leads to reversible immune dysfunction. Nat Med 12(10):1198\u20131202","journal-title":"Nat Med"},{"key":"1343_CR182","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-12-199512150-00006","author":"Trends in Infectious Diseases and Cancers among Persons Dying of HIV Infection in the United States","year":"1995","unstructured":"Trends in Infectious Diseases and Cancers among Persons Dying of HIV Infection in the United States from 1987 to 1992 (1995) Ann Intern Med 123(12): 933-936 https:\/\/doi.org\/10.7326\/0003-4819-123-12-199512150-00006"},{"issue":"3","key":"1343_CR183","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.molcel.2016.07.004","volume":"63","author":"J Tycko","year":"2016","unstructured":"Tycko J, Myer VE, Hsu PD (2016) Methods for optimizing CRISPR-Cas9 genome editing specificity. Mol Cell 63(3):355\u2013370","journal-title":"Mol Cell"},{"key":"1343_CR184","unstructured":"Vaillant A, Jamal Z, Patel P, Ramphul K (2023) Immunoglobulin. Stat. Pearls. In: StatPearls Publishing"},{"issue":"9","key":"1343_CR185","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nri1182","volume":"3","author":"Y van Kooyk","year":"2003","unstructured":"van Kooyk Y, Geijtenbeek TB (2003) DC-SIGN: escape mechanism for pathogens. Nat Rev Immunol 3(9):697\u2013709","journal-title":"Nat Rev Immunol"},{"key":"1343_CR186","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-4690-10-67","volume":"10","author":"C Van Lint","year":"2013","unstructured":"Van Lint C, Bouchat S, Marcello A (2013) HIV-1 transcription and latency: an update. Retrovirology 10:1\u201338","journal-title":"Retrovirology"},{"issue":"9","key":"1343_CR187","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1172\/JCI65175","volume":"122","author":"CG Vinuesa","year":"2012","unstructured":"Vinuesa CG (2012) HIV and T follicular helper cells: a dangerous relationship. J Clin Investig 122(9):3059\u20133062","journal-title":"J Clin Investig"},{"issue":"21","key":"1343_CR188","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/NEJMoa0800971","volume":"359","author":"A Violari","year":"2008","unstructured":"Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, Jean-Philippe P, McIntyre JA (2008) Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 359(21):2233\u20132244. https:\/\/doi.org\/10.1056\/NEJMoa0800971","journal-title":"N Engl J Med"},{"key":"1343_CR189","doi-asserted-by":"crossref","unstructured":"Vos AG, Venter WDF (2021) Cardiovascular toxicity of contemporary antiretroviral therapy. Curr Opin HIV AIDS 16(6). https:\/\/journals.lww.com\/co-hivandaids\/fulltext\/2021\/11000\/cardiovascular_toxicity_of_contemporary.3.aspx","DOI":"10.1097\/COH.0000000000000702"},{"issue":"5","key":"1343_CR190","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nri.2017.148","volume":"18","author":"LM Walker","year":"2018","unstructured":"Walker LM, Burton DR (2018) Passive immunotherapy of viral infections:\u2018super-antibodies\u2019 enter the fray. Nat Rev Immunol 18(5):297\u2013308","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"1343_CR193","doi-asserted-by":"publisher","first-page":"e115987","DOI":"10.1371\/journal.pone.0115987","volume":"9","author":"W Wang","year":"2014","unstructured":"Wang W, Ye C, Liu J, Zhang D, Kimata JT, Zhou P (2014) CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. PLoS ONE 9(12):e115987","journal-title":"PLoS ONE"},{"issue":"1","key":"1343_CR191","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12977-017-0375-0","volume":"14","author":"Q Wang","year":"2017","unstructured":"Wang Q, Chen S, Xiao Q, Liu Z, Liu S, Hou P, Zhou L, Hou W, Ho W, Li C, Wu L, Guo D (2017) Genome modification of CXCR4 by Staphylococcus aureus Cas9 renders cells resistance to HIV-1 infection. Retrovirology 14(1):51. https:\/\/doi.org\/10.1186\/s12977-017-0375-0","journal-title":"Retrovirology"},{"key":"1343_CR192","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.virusres.2018.04.002","volume":"250","author":"Q Wang","year":"2018","unstructured":"Wang Q, Liu S, Liu Z, Ke Z, Li C, Yu X, Chen S, Guo D (2018) Genome scale screening identification of SaCas9\/gRNAs for targeting HIV-1 provirus and suppression of HIV-1 infection. Virus Res 250:21\u201330. https:\/\/doi.org\/10.1016\/j.virusres.2018.04.002","journal-title":"Virus Res"},{"key":"1343_CR194","doi-asserted-by":"publisher","first-page":"101412","DOI":"10.1016\/j.smim.2020.101412","volume":"51","author":"AR Ward","year":"2021","unstructured":"Ward AR, Mota TM, Jones RB (2021) Immunological approaches to HIV cure. Semin Immunol 51:101412. https:\/\/doi.org\/10.1016\/j.smim.2020.101412","journal-title":"Semin Immunol"},{"issue":"3","key":"1343_CR195","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.cjca.2018.11.005","volume":"35","author":"DD Waters","year":"2019","unstructured":"Waters DD, Hsue PY (2019) Lipid Abnormalities in Persons Living With HIV Infection. Can J Cardiol 35(3):249\u2013259. https:\/\/doi.org\/10.1016\/j.cjca.2018.11.005","journal-title":"Can J Cardiol"},{"issue":"4","key":"1343_CR196","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/QAD.0000000000000562","volume":"29","author":"F Wightman","year":"2015","unstructured":"Wightman F, Solomon A, Kumar SS, Urriola N, Gallagher K, Hiener B, Palmer S, Mcneil C, Garsia R, Lewin SR (2015) Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma. Aids 29(4):504\u2013506","journal-title":"Aids"},{"issue":"8","key":"1343_CR197","doi-asserted-by":"publisher","first-page":"a006866","DOI":"10.1101\/cshperspect.a006866","volume":"2","author":"CB Wilen","year":"2012","unstructured":"Wilen CB, Tilton JC, Doms RW (2012) HIV: cell binding and entry. Cold Spring Harbor Perspect Med 2(8):a006866","journal-title":"Cold Spring Harbor Perspect Med"},{"issue":"12","key":"1343_CR198","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1097\/00002030-199908200-00006","volume":"13","author":"M Witvrouw","year":"1999","unstructured":"Witvrouw M, Pannecouque C, Van Laethem K, Desmyter J, De Clercq E, Vandamme A-M (1999) Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. Aids 13(12):1477\u20131483","journal-title":"Aids"},{"key":"1343_CR199","unstructured":"World Health Organization (W.H.O.). HIV\/AIDS (2024) https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids"},{"issue":"1","key":"1343_CR201","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12977-019-0477-y","volume":"16","author":"Q Xiao","year":"2019","unstructured":"Xiao Q, Chen S, Wang Q, Liu Z, Liu S, Deng H, Hou W, Wu D, Xiong Y, Li J, Guo D (2019) CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4\u2009+\u2009T cells and hematopoietic stem\/progenitor cells promotes HIV-1 resistance and CD4\u2009+\u2009T cell enrichment in humanized mice. Retrovirology 16(1):15. https:\/\/doi.org\/10.1186\/s12977-019-0477-y","journal-title":"Retrovirology"},{"issue":"8","key":"1343_CR202","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1016\/j.ymthe.2017.04.027","volume":"25","author":"L Xu","year":"2017","unstructured":"Xu L, Yang H, Gao Y, Chen Z, Xie L, Liu Y, Liu Y, Wang X, Li H, Lai W (2017) CRISPR\/Cas9-mediated CCR5 ablation in human hematopoietic stem\/progenitor cells confers HIV-1 resistance in vivo. Mol Ther 25(8):1782\u20131789","journal-title":"Mol Ther"},{"issue":"1","key":"1343_CR203","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1186\/s12967-024-05957-3","volume":"22","author":"W Xu","year":"2024","unstructured":"Xu W, Zhang S, Qin H, Yao K (2024) From bench to bedside: cutting-edge applications of base editing and prime editing in precision medicine. J Translational Med 22(1):1133. https:\/\/doi.org\/10.1186\/s12967-024-05957-3","journal-title":"J Translational Med"},{"issue":"7","key":"1343_CR204","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.tig.2021.02.008","volume":"37","author":"C Xue","year":"2021","unstructured":"Xue C, Greene EC (2021) DNA Repair Pathway Choices in CRISPR-Cas9-Mediated Genome Editing. Trends Genet 37(7):639\u2013656. https:\/\/doi.org\/10.1016\/j.tig.2021.02.008","journal-title":"Trends Genet"},{"issue":"8","key":"1343_CR205","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1080\/17425247.2022.2100342","volume":"19","author":"W Yang","year":"2022","unstructured":"Yang W, Yan J, Zhuang P, Ding T, Chen Y, Zhang Y, Zhang H, Cui W (2022) Progress of delivery methods for CRISPR-Cas9. Expert Opin Drug Deliv 19(8):913\u2013926. https:\/\/doi.org\/10.1080\/17425247.2022.2100342","journal-title":"Expert Opin Drug Deliv"},{"issue":"8","key":"1343_CR206","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1097\/QAD.0000000000001079","volume":"30","author":"C Yin","year":"2016","unstructured":"Yin C, Zhang T, Li F, Yang F, Putatunda R, Young W-B, Khalili K, Hu W, Zhang Y (2016a) Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of AIDS. Aids 30(8):1163\u20131173","journal-title":"Aids"},{"issue":"3","key":"1343_CR208","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nbt.3471","volume":"34","author":"H Yin","year":"2016","unstructured":"Yin H, Song C-Q, Dorkin JR, Zhu LJ, Li Y, Wu Q, Park A, Yang J, Suresh S, Bizhanova A (2016b) Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol 34(3):328\u2013333","journal-title":"Nat Biotechnol"},{"issue":"5","key":"1343_CR207","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.ymthe.2017.03.012","volume":"25","author":"C Yin","year":"2017","unstructured":"Yin C, Zhang T, Qu X, Zhang Y, Putatunda R, Xiao X, Li F, Xiao W, Zhao H, Dai S, Qin X, Mo X, Young WB, Khalili K, Hu W (2017) In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models. Mol Ther 25(5):1168\u20131186. https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.012","journal-title":"Mol Ther"},{"key":"1343_CR209","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.omtn.2020.05.030","volume":"21","author":"L Yin","year":"2020","unstructured":"Yin L, Zhao F, Sun H, Wang Z, Huang Y, Zhu W, Xu F, Mei S, Liu X, Zhang D, Wei L, Cen S, Hu S, Liang C, Guo F (2020) CRISPR-Cas13a Inhibits HIV-1 Infection. Mol Ther Nucleic Acids 21:147\u2013155. https:\/\/doi.org\/10.1016\/j.omtn.2020.05.030","journal-title":"Mol Ther Nucleic Acids"},{"issue":"7","key":"1343_CR210","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1172\/JCI85996","volume":"126","author":"S-A Younes","year":"2016","unstructured":"Younes S-A, Freeman ML, Mudd JC, Shive CL, Reynaldi A, Panigrahi S, Estes JD, Deleage C, Lucero C, Anderson J (2016) IL-15 promotes activation and expansion of CD8\u2009+\u2009T cells in HIV-1 infection. J Clin Investig 126(7):2745\u20132756","journal-title":"J Clin Investig"},{"issue":"3","key":"1343_CR211","first-page":"242","volume":"103","author":"FE Young","year":"1988","unstructured":"Young FE (1988) The role of the FDA in the effort against AIDS. Public Health Rep 103(3):242","journal-title":"Public Health Rep"},{"issue":"2","key":"1343_CR212","doi-asserted-by":"publisher","first-page":"614","DOI":"10.7150\/thno.47007","volume":"11","author":"S Zhang","year":"2021","unstructured":"Zhang S, Shen J, Li D, Cheng Y (2021) Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR\/Cas9 genome editing. Theranostics 11(2):614\u2013648. https:\/\/doi.org\/10.7150\/thno.47007","journal-title":"Theranostics"},{"issue":"1","key":"1343_CR213","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12977-015-0150-z","volume":"12","author":"W Zhu","year":"2015","unstructured":"Zhu W, Lei R, Le Duff Y, Li J, Guo F, Wainberg MA, Liang C (2015) The CRISPR\/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology 12(1):22","journal-title":"Retrovirology"},{"issue":"1","key":"1343_CR214","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.antiviral.2009.10.018","volume":"85","author":"AR Zolopa","year":"2010","unstructured":"Zolopa AR (2010) The evolution of HIV treatment guidelines: Current state-of-the-art of ART. Antiviral Res 85(1):241\u2013244. https:\/\/doi.org\/10.1016\/j.antiviral.2009.10.018","journal-title":"Antiviral Res"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-026-01343-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13365-026-01343-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-026-01343-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:02:43Z","timestamp":1791298963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13365-026-01343-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":214,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1343"],"URL":"https:\/\/doi.org\/10.1007\/s13365-026-01343-5","relation":{"references":[{"id-type":"doi","id":"10.7326\/0003-4819-123-12-199512150-00006%m","asserted-by":"subject"}]},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"18 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"42"}}